<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">34226958</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0460</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Dysphagia</Title>
          <ISOAbbreviation>Dysphagia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Autoimmune Neurogenic Dysphagia.</ArticleTitle>
        <Pagination>
          <StartPage>473</StartPage>
          <EndPage>487</EndPage>
          <MedlinePgn>473-487</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00455-021-10338-9</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune neurogenic dysphagia refers to manifestation of dysphagia due to autoimmune diseases affecting muscle, neuromuscular junction, nerves, roots, brainstem, or cortex. Dysphagia is either part of the evolving clinical symptomatology of an underlying neurological autoimmunity or occurs as a sole manifestation, acutely or insidiously. This opinion article reviews the autoimmune neurological causes of dysphagia, highlights clinical clues and laboratory testing that facilitate early diagnosis, especially when dysphagia is the presenting symptom, and outlines the most effective immunotherapeutic approaches. Dysphagia is common in inflammatory myopathies, most prominently in inclusion body myositis, and is frequent in myasthenia gravis, occurring early in bulbar-onset disease or during the course of progressive, generalized disease. Acute-onset dysphagia is often seen in Guillain-Barre syndrome variants and slowly progressive dysphagia in paraneoplastic neuropathies highlighted by the presence of specific autoantibodies. The most common causes of CNS autoimmune dysphagia are demyelinating and inflammatory lesions in the brainstem, occurring in patients with multiple sclerosis and neuromyelitis optica spectrum disorders. Less common, but often overlooked, is dysphagia in stiff-person syndrome especially in conjunction with cerebellar ataxia and high anti-GAD autoantibodies, and in gastrointestinal dysmotility syndromes associated with autoantibodies against the ganglionic acetyl-choline receptor. In the setting of many neurological autoimmunities, acute-onset or progressive dysphagia is a potentially treatable condition, requiring increased awareness for prompt diagnosis and early immunotherapy initiation.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Stathopoulos</LastName>
            <ForeName>Panos</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Neurology, National and Kapodistrian University of Athens Medical School, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dalakas</LastName>
            <ForeName>Marinos C</ForeName>
            <Initials>MC</Initials>
            <Identifier Source="ORCID">0000-0001-7070-1134</Identifier>
            <AffiliationInfo>
              <Affiliation>Neuroimmunology Unit, Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece. marinos.dalakas@jefferson.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Thomas Jefferson University, Philadelphia, USA. marinos.dalakas@jefferson.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Dysphagia</MedlineTA>
        <NlmUniqueID>8610856</NlmUniqueID>
        <ISSNLinking>0179-051X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003680" MajorTopicYN="Y">Deglutition Disorders</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autoimmune neuropathies</Keyword>
        <Keyword MajorTopicYN="N">Deglutition</Keyword>
        <Keyword MajorTopicYN="N">Deglutition disorders</Keyword>
        <Keyword MajorTopicYN="N">Dysphagia</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapies</Keyword>
        <Keyword MajorTopicYN="N">Inflammatory myopathies</Keyword>
        <Keyword MajorTopicYN="N">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Neurological autoimmunity</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis</Keyword>
        <Keyword MajorTopicYN="N">Stiff-person syndrome</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34226958</ArticleId>
        <ArticleId IdType="pmc">PMC8257036</ArticleId>
        <ArticleId IdType="doi">10.1007/s00455-021-10338-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00455-021-10338-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82. doi: 10.1016/S0140-6736(03)14368-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(03)14368-1</ArticleId>
            <ArticleId IdType="pubmed">14511932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487–98. doi: 10.1056/NEJM199111213252107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199111213252107</ArticleId>
            <ArticleId IdType="pubmed">1658649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734–47. doi: 10.1056/NEJMra1402225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1402225</ArticleId>
            <ArticleId IdType="pubmed">25923553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al.  A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360–74. doi: 10.1097/00005792-199111000-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-199111000-00002</ArticleId>
            <ArticleId IdType="pubmed">1659647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labeit B, Pawlitzki M, Ruck T, Muhle P, Claus I, Suntrup-Krueger S, et al.  The impact of dysphagia in myositis: a systematic review and meta-analysis. JCM. 2020;9:2150. doi: 10.3390/jcm9072150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm9072150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobloug C, Garen T, Bitter H, Stjärne J, Stenseth G, Grøvle L, et al.  Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2015;74:1551–6. doi: 10.1136/annrheumdis-2013-205127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-205127</ArticleId>
            <ArticleId IdType="pubmed">24695011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ríos G. Retrospective review of the clinical manifestations and outcomes in puerto ricans with idiopathic inflammatory myopathies. JCR J Clin Rheumatol. 2005;11:153–6. doi: 10.1097/01.rhu.0000164820.46979.52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.rhu.0000164820.46979.52</ArticleId>
            <ArticleId IdType="pubmed">16357735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28. doi: 10.1007/s11926-018-0733-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11926-018-0733-5</ArticleId>
            <ArticleId IdType="pubmed">29637414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheehan NJ. Dysphagia and other manifestations of oesophageal involvement in the musculoskeletal diseases. Rheumatology. 2008;47:746–52. doi: 10.1093/rheumatology/ken029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/ken029</ArticleId>
            <ArticleId IdType="pubmed">18326539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al.  The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77:30–9. doi: 10.1136/annrheumdis-2017-211868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-211868</ArticleId>
            <ArticleId IdType="pmc">PMC5754739</ArticleId>
            <ArticleId IdType="pubmed">28855174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Basford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–7. doi: 10.4065/82.4.441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/82.4.441</ArticleId>
            <ArticleId IdType="pubmed">17418072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triplett JD, Pinto MV, Hosfield EA, Milone M, Liewluck T. Myopathies featuring early or prominent dysphagia. Muscle Nerve. 2020;62:344–50. doi: 10.1002/mus.26996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26996</ArticleId>
            <ArticleId IdType="pubmed">32510670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000. doi: 10.1056/NEJM199312303292704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199312303292704</ArticleId>
            <ArticleId IdType="pubmed">8247075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. J Neurol Neurosurg Psychiatry. 2016;87:1037. doi: 10.1136/jnnp-2016-313418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2016-313418</ArticleId>
            <ArticleId IdType="pubmed">27151962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Are autoantibodies pathogenic in necrotizing myopathy? Nat Rev Rheumatol. 2018;14:251–2. doi: 10.1038/nrrheum.2018.54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2018.54</ArticleId>
            <ArticleId IdType="pubmed">29651118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Case 22–2019: a 65-year-old woman with myopathy. N Engl J Med. 2019;381:1693. doi: 10.1056/NEJMc1911058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1911058</ArticleId>
            <ArticleId IdType="pubmed">31644862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167–75. doi: 10.1093/brain/awr217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awr217</ArticleId>
            <ArticleId IdType="pubmed">21908393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taira K, Yamamoto T, Mori-Yoshimura M, Fujita S, Oya Y, Nishino I, et al.  Obstruction-related dysphagia in inclusion body myositis: cricopharyngeal bar on videofluoroscopy indicates risk of aspiration. J Neurol Sci. 2020;413:116764. doi: 10.1016/j.jns.2020.116764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2020.116764</ArticleId>
            <ArticleId IdType="pubmed">32172012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256:2009–13. doi: 10.1007/s00415-009-5229-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5229-9</ArticleId>
            <ArticleId IdType="pmc">PMC2780610</ArticleId>
            <ArticleId IdType="pubmed">19603245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope. 1998;108:1001–5. doi: 10.1097/00005537-199807000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005537-199807000-00009</ArticleId>
            <ArticleId IdType="pubmed">9665246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6. doi: 10.1212/WNL.48.3.712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.48.3.712</ArticleId>
            <ArticleId IdType="pubmed">9065553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51:1542–5. doi: 10.1136/jnnp.51.12.1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.51.12.1542</ArticleId>
            <ArticleId IdType="pmc">PMC1032771</ArticleId>
            <ArticleId IdType="pubmed">2851642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43:1241–1. doi: 10.1212/WNL.43.6.1241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.43.6.1241</ArticleId>
            <ArticleId IdType="pubmed">8170574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain. 1989;112:727–47. doi: 10.1093/brain/112.3.727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/112.3.727</ArticleId>
            <ArticleId IdType="pubmed">2543478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132:1536–44. doi: 10.1093/brain/awp104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awp104</ArticleId>
            <ArticleId IdType="pmc">PMC2685923</ArticleId>
            <ArticleId IdType="pubmed">19454532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm. 2019;6:e581. doi: 10.1212/NXI.0000000000000581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000581</ArticleId>
            <ArticleId IdType="pmc">PMC6624107</ArticleId>
            <ArticleId IdType="pubmed">31355317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334:123–5. doi: 10.1016/j.jns.2013.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2013.08.007</ArticleId>
            <ArticleId IdType="pubmed">23998706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al.  Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73:913–20. doi: 10.1136/annrheumdis-2012-202857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-202857</ArticleId>
            <ArticleId IdType="pubmed">23625983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMillan RA, Bowen AJ, Bayan SL, Kasperbauer JL, Ekbom DC. Cricopharyngeal myotomy in inclusion body myositis: comparison of endoscopic and transcervical approaches. Laryngoscope. 2021 doi: 10.1002/lary.29444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lary.29444</ArticleId>
            <ArticleId IdType="pubmed">34236086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87:883–9. doi: 10.1097/PHM.0b013e31818a50e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PHM.0b013e31818a50e2</ArticleId>
            <ArticleId IdType="pubmed">18936555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata K, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep. 2013;6:CCRep.S10200. doi: 10.4137/CCRep.S10200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/CCRep.S10200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. IJGM. 2019;12:465–74. doi: 10.2147/IJGM.S198031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJGM.S198031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng R, Schmidt J. Impact and management of dysphagia in inflammatory myopathies. Curr Rheumatol Rep. 2020;22:74. doi: 10.1007/s11926-020-00950-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11926-020-00950-3</ArticleId>
            <ArticleId IdType="pubmed">32860119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology. 2000;55:296–8. doi: 10.1212/WNL.55.2.296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.2.296</ArticleId>
            <ArticleId IdType="pubmed">10908910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453–77. doi: 10.1002/(SICI)1097-4598(200004)23:4&lt;453::AID-MUS3&gt;3.0.CO;2-O.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-4598(200004)23:4&lt;453::AID-MUS3&gt;3.0.CO;2-O</ArticleId>
            <ArticleId IdType="pubmed">10716755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–8. doi: 10.1038/85520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/85520</ArticleId>
            <ArticleId IdType="pubmed">11231638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handbook of Clinical Neurology [Internet]. Elsevier; 2016 [cited 2020 Sep 21]. p. 447–66. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780444634320000244</Citation>
        </Reference>
        <Reference>
          <Citation>Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978–80. doi: 10.1212/01.WNL.0000065882.63904.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000065882.63904.53</ArticleId>
            <ArticleId IdType="pubmed">12821744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray JP. Deglutition in myasthenia gravis. BJR. 1962;35:43–52. doi: 10.1259/0007-1285-35-409-43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1259/0007-1285-35-409-43</ArticleId>
            <ArticleId IdType="pubmed">14477472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llabres M. Dysphagia as the sole manifestation of myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005;76:1297–300. doi: 10.1136/jnnp.2004.038430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2004.038430</ArticleId>
            <ArticleId IdType="pmc">PMC1739805</ArticleId>
            <ArticleId IdType="pubmed">16107373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang MH, King KL, Chien KY. Esophageal manometric studies in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 1988;95:281–5. doi: 10.1016/S0022-5223(19)35365-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-5223(19)35365-6</ArticleId>
            <ArticleId IdType="pubmed">3339894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci. 1987;505:472–99. doi: 10.1111/j.1749-6632.1987.tb51317.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1987.tb51317.x</ArticleId>
            <ArticleId IdType="pubmed">3318620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology*. Incidence of myasthenia gravis in the Emilia-Romagna region: A prospective multicenter study. Neurology. 1998;51: 255–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Carpenter RJ, Mcdonald TJ, Howard FM. The otolaryngologic presentation of myasthenia gravis. Laryngoscope. 1979;89:922???928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">449537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arellano-Aguilar G, Núñez-Mojica ES, Gutiérrez-Velazco JL, Domínguez-Carrillo LG. Paraneoplastic Lambert-Eaton syndrome in a patient with disseminated metastatic cancer. CIRUE. 2019;86:1948. doi: 10.24875/CIRUE.M18000011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.24875/CIRUE.M18000011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15:113–24. doi: 10.1038/s41582-018-0110-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-018-0110-z</ArticleId>
            <ArticleId IdType="pubmed">30573759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology. 1997;48:64S–9S. doi: 10.1212/WNL.48.Suppl_5.64S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.48.Suppl_5.64S</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16:601–17. doi: 10.1038/s41582-020-0400-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-020-0400-0</ArticleId>
            <ArticleId IdType="pmc">PMC7528717</ArticleId>
            <ArticleId IdType="pubmed">33005040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lünemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13:34–46. doi: 10.1007/s13311-015-0391-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-015-0391-5</ArticleId>
            <ArticleId IdType="pmc">PMC4720677</ArticleId>
            <ArticleId IdType="pubmed">26400261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia) N Engl J Med. 1956;255:57–65. doi: 10.1056/NEJM195607122550201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM195607122550201</ArticleId>
            <ArticleId IdType="pubmed">13334797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64:1519–23. doi: 10.1001/archneur.64.10.1519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.64.10.1519</ArticleId>
            <ArticleId IdType="pubmed">17923636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339–44. doi: 10.1136/jnnp-2013-305397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2013-305397</ArticleId>
            <ArticleId IdType="pubmed">23804237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arakawa M, Yamazaki M, Toda Y, Ozawa A, Kimura K. An oculopharyngeal subtype of Guillain-Barré syndrome sparing the trochlear and abducens nerves. Intern Med. 2020;59:1215–7. doi: 10.2169/internalmedicine.3395-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.3395-19</ArticleId>
            <ArticleId IdType="pmc">PMC7270762</ArticleId>
            <ArticleId IdType="pubmed">32023583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel K, Nussbaum E, Sico J, Merchant N. Atypical case of Miller-Fisher syndrome presenting with severe dysphagia and weight loss. BMJ Case Rep. 2020;13:e234316. doi: 10.1136/bcr-2020-234316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2020-234316</ArticleId>
            <ArticleId IdType="pmc">PMC7259814</ArticleId>
            <ArticleId IdType="pubmed">32467120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edvardsson B, Persson S. Polyneuritis cranialis presenting with anti-GQ1b IgG antibody. J Neurol Sci. 2009;281:125–6. doi: 10.1016/j.jns.2009.02.340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2009.02.340</ArticleId>
            <ArticleId IdType="pubmed">19324375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilyas AA, Cook SD, Mithen FA, Taki T, Kasama T, Handa S, et al.  Antibodies to GT1a ganglioside in patients with Guillain-Barré syndrome. J Neuroimmunol. 1998;82:160–7. doi: 10.1016/S0165-5728(97)00197-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(97)00197-5</ArticleId>
            <ArticleId IdType="pubmed">9585812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Muñoz-Jordan JL, et al.  Clinical features of Guillain-Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol. 2018;75:1089. doi: 10.1001/jamaneurol.2018.1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.1058</ArticleId>
            <ArticleId IdType="pmc">PMC6143122</ArticleId>
            <ArticleId IdType="pubmed">29799940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlikowski D, Terzi N, Blumen M, Sharshar T, Raphael JC, Annane D, et al.  Tongue weakness is associated with respiratory failure in patients with severe Guillain-Barré syndrome. Acta Neurol Scand. 2009;119:364–70. doi: 10.1111/j.1600-0404.2008.01107.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2008.01107.x</ArticleId>
            <ArticleId IdType="pubmed">18976323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen MYM, Donofrio PD, Frederick MG, Ott DJ, Pikna LA. Videofluoroscopic evaluation of patients with Guillain-Barré syndrome. Dysphagia. 1996;11:11–3. doi: 10.1007/BF00385793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00385793</ArticleId>
            <ArticleId IdType="pubmed">8556871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mengi T, Seçil Y, İncesu TK, Arici Ş, Akkiraz ZÖ, Gürgör N, et al.  Guillain-Barré syndrome and swallowing dysfunction. J Clin Neurophysiol. 2017;34:393–9. doi: 10.1097/WNP.0000000000000380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNP.0000000000000380</ArticleId>
            <ArticleId IdType="pubmed">28873071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Guillain-Barré syndrome: the first documented COVID-19–triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7:e781. doi: 10.1212/NXI.0000000000000781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000781</ArticleId>
            <ArticleId IdType="pmc">PMC7309518</ArticleId>
            <ArticleId IdType="pubmed">32518172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costello F, Dalakas MC. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity. Neurology. 2020;95:195–6. doi: 10.1212/WNL.0000000000009921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000009921</ArticleId>
            <ArticleId IdType="pubmed">32487714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley &amp; Sons, Ltd; 2010 [cited 2020 Sep 27]. p. CD002063.pub4. Available from: http://doi.wiley.com/10.1002/14651858.CD002063.pub4</Citation>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367–75. doi: 10.1001/jama.291.19.2367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.291.19.2367</ArticleId>
            <ArticleId IdType="pubmed">15150209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teramoto H, Morita A, Hara M, Ninomiya S, Shigihara S, Kusunoki S, et al.  Relapse with dysphagia in a case of chronic inflammatory demyelinating polyradiculoneuropathy. Intern Med. 2015;54:1791–3. doi: 10.2169/internalmedicine.54.4300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.54.4300</ArticleId>
            <ArticleId IdType="pubmed">26179538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzucco S, Ferrari S, Mezzina C, Tomelleri G, Bertolasi L, Rizzuto N. Hyperpyrexia-triggered relapses in an unusual case of ataxic chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Sci. 2006;27:176–9. doi: 10.1007/s10072-006-0664-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-006-0664-1</ArticleId>
            <ArticleId IdType="pubmed">16897630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al.  Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149. doi: 10.1212/NXI.0000000000000149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000149</ArticleId>
            <ArticleId IdType="pmc">PMC4561230</ArticleId>
            <ArticleId IdType="pubmed">26401517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Schaik IN, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, et al.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46. doi: 10.1016/S1474-4422(17)30378-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(17)30378-2</ArticleId>
            <ArticleId IdType="pubmed">29122523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry. 2010;81:634–6. doi: 10.1136/jnnp.2009.177576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.177576</ArticleId>
            <ArticleId IdType="pubmed">20176598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyck PJ, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35:1173–6. doi: 10.1212/WNL.35.8.1173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.35.8.1173</ArticleId>
            <ArticleId IdType="pubmed">4022350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012;18:463–8. doi: 10.1097/PPO.0b013e31826c5ad5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PPO.0b013e31826c5ad5</ArticleId>
            <ArticleId IdType="pubmed">23006953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zekeridou A, Lennon VA. Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc. 2019;94:1865–78. doi: 10.1016/j.mayocp.2019.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2019.02.003</ArticleId>
            <ArticleId IdType="pubmed">31358366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you “take the brakes off” the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6144585</ArticleId>
            <ArticleId IdType="pubmed">30245744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muppidi S, Vernino S. Paraneoplastic neuropathies. Continuum (Minneap Minn) 2014;20:1359–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25299287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmau J. Paraneoplastic neuropathies. Curr Opin Neurol. 2013;26:489–95. doi: 10.1097/WCO.0b013e328364c020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0b013e328364c020</ArticleId>
            <ArticleId IdType="pubmed">23892629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999;67:7–14. doi: 10.1136/jnnp.67.1.7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.67.1.7</ArticleId>
            <ArticleId IdType="pmc">PMC1736440</ArticleId>
            <ArticleId IdType="pubmed">10369814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viala K, Béhin A, Maisonobe T, Léger J-M, Stojkovic T, Davi F, et al.  Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008;79:778–82. doi: 10.1136/jnnp.2007.125930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.125930</ArticleId>
            <ArticleId IdType="pubmed">17971432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni J, Weng L, Liu M, Yang H, Wang Y. Small cell lung cancer accompanied by tonsillar metastasis and anti-hu antibody-associated paraneoplastic neuropathy: a rare case report with long-term survival. Medicine. 2015;94:e2291. doi: 10.1097/MD.0000000000002291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000002291</ArticleId>
            <ArticleId IdType="pmc">PMC5058936</ArticleId>
            <ArticleId IdType="pubmed">26683964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung JC, Pringle CE, Sekhon HS, Kilty SJ, Macdonald K. Bilateral vocal cord paralysis and cervicolumbar radiculopathy as the presenting paraneoplastic manifestations of small cell lung cancer: a case report and literature review. Case Rep Otolaryngol. 2016;2016:1–5. doi: 10.1155/2016/2868190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/2868190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580–7. doi: 10.1002/ana.10518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10518</ArticleId>
            <ArticleId IdType="pubmed">12730991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al.  Neurosarcoidosis: presentations and management. Neurologist. 2010;16:2–15. doi: 10.1097/NRL.0b013e3181c92a72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NRL.0b013e3181c92a72</ArticleId>
            <ArticleId IdType="pubmed">20065791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brito-Zerón P, Bari K, Baughman RP, Ramos-Casals M. Sarcoidosis involving the gastrointestinal tract: diagnostic and therapeutic management. Am J Gastroenterol. 2019;114:1238–47. doi: 10.14309/ajg.0000000000000171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000171</ArticleId>
            <ArticleId IdType="pubmed">30865014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishikubo K, Hyodo M, Kawakami M, Kobayashi T. A rare manifestation of cricopharyngeal myopathy presenting with dysphagia in sarcoidosis. Rheumatol Int. 2013;33:1089–92. doi: 10.1007/s00296-011-2242-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-011-2242-y</ArticleId>
            <ArticleId IdType="pubmed">22116526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732. doi: 10.1177/1756286418805732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756286418805732</ArticleId>
            <ArticleId IdType="pmc">PMC6204624</ArticleId>
            <ArticleId IdType="pubmed">30386436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, et al.  Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012;39:27–33. doi: 10.1016/j.jaut.2012.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2012.01.003</ArticleId>
            <ArticleId IdType="pubmed">22318209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, et al.  Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82:798–802. doi: 10.1136/jnnp.2010.222109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2010.222109</ArticleId>
            <ArticleId IdType="pubmed">21172862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41:203–11. doi: 10.1016/j.semarthrit.2011.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2011.04.001</ArticleId>
            <ArticleId IdType="pubmed">21641018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edmonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J. 1979;2:173–5. doi: 10.1136/bmj.2.6183.173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.2.6183.173</ArticleId>
            <ArticleId IdType="pmc">PMC1595852</ArticleId>
            <ArticleId IdType="pubmed">466338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poglio F, Mongini T, Cocito D. Sensory ataxic neuropathy and esophageal achalasia in a patient with Sjogren’s syndrome. Muscle Nerve. 2007;35:532–5. doi: 10.1002/mus.20716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20716</ArticleId>
            <ArticleId IdType="pubmed">17221876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez JMS, McNally JS, Cortez MM, Hemp J, Pace LA, Clardy SL. Neuroimmunogastroenterology: at the interface of neuroimmunology and gastroenterology. Front Neurol. 2020;11:787. doi: 10.3389/fneur.2020.00787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00787</ArticleId>
            <ArticleId IdType="pmc">PMC7412790</ArticleId>
            <ArticleId IdType="pubmed">32849234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhamija R, Tan KM, Pittock SJ, Foxx-Orenstein A, Benarroch E, Lennon VA. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol. 2008;6:988–92. doi: 10.1016/j.cgh.2008.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2008.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC2741093</ArticleId>
            <ArticleId IdType="pubmed">18599359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukaino A, Minami H, Isomoto H, Hamamoto H, Ihara E, Maeda Y, et al.  Anti-ganglionic AChR antibodies in Japanese patients with motility disorders. J Gastroenterol. 2018;53:1227–40. doi: 10.1007/s00535-018-1477-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-018-1477-8</ArticleId>
            <ArticleId IdType="pubmed">29766276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Amico E, Zanghì A, Serra A, Murabito P, Zappia M, Patti F, et al.  Management of dysphagia in multiple sclerosis: current best practice. Expert Rev Gastroenterol Hepatol. 2019;13:47–54. doi: 10.1080/17474124.2019.1544890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17474124.2019.1544890</ArticleId>
            <ArticleId IdType="pubmed">30791843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tassorelli C, Bergamaschi R, Buscone S, Bartolo M, Furnari A, Crivelli P, et al.  Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurol Sci. 2008;29:360–3. doi: 10.1007/s10072-008-1044-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-008-1044-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pender MP, Ferguson SM. Dysarthria and dysphagia due to the opercular syndrome in multiple sclerosis. Mult Scler. 2007;13:817–9. doi: 10.1177/1352458506073481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458506073481</ArticleId>
            <ArticleId IdType="pubmed">17613613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan X-L, Wang H, Huang H-S, Meng L. Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2015;36:671–81. doi: 10.1007/s10072-015-2067-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-015-2067-7</ArticleId>
            <ArticleId IdType="pubmed">25647290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci. 1981;49:253–71. doi: 10.1016/0022-510X(81)90083-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(81)90083-6</ArticleId>
            <ArticleId IdType="pubmed">7217984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46:9–17. doi: 10.1159/000266286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000266286</ArticleId>
            <ArticleId IdType="pubmed">8162135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levinthal DJ, Rahman A, Nusrat S, O’Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:1–9. doi: 10.1155/2013/319201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/319201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, et al.  Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire) J Neurol Sci. 2013;331:94–7. doi: 10.1016/j.jns.2013.05.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2013.05.020</ArticleId>
            <ArticleId IdType="pubmed">23747002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danesh-Sani SA, Rahimdoost A, Soltani M, Ghiyasi M, Haghdoost N, Sabzali-Zanjankhah S. Clinical assessment of orofacial manifestations in 500 patients with multiple sclerosis. J Oral Maxillofac Surg. 2013;71:290–4. doi: 10.1016/j.joms.2012.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.joms.2012.05.008</ArticleId>
            <ArticleId IdType="pubmed">22742955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham S, Scheinberg LC, Smith CR, LaRocca NG. Neurologic impairment and disability status in outpatients with multiple sclerosis reporting dysphagia symptomatology. Neurorehabil Neural Repair. 1997;11:7–13. doi: 10.1177/154596839701100102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/154596839701100102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Pauw A, Dejaeger E, D’hooghe B, Carton H. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg. 2002;104:345–51. doi: 10.1016/S0303-8467(02)00053-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0303-8467(02)00053-7</ArticleId>
            <ArticleId IdType="pubmed">12140103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandes AMF, de Campos DA, Eckley CA, da Silva L, Ferreira RB, Tilbery CP. Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity? Braz J Otorhinolaryngol. 2013;79:460–5. doi: 10.5935/1808-8694.20130082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5935/1808-8694.20130082</ArticleId>
            <ArticleId IdType="pubmed">23929146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfonsi E, Bergamaschi R, Cosentino G, Ponzio M, Montomoli C, Restivo DA, et al.  Electrophysiological patterns of oropharyngeal swallowing in multiple sclerosis. Clin Neurophysiol. 2013;124:1638–45. doi: 10.1016/j.clinph.2013.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2013.03.003</ArticleId>
            <ArticleId IdType="pubmed">23601703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiesner W, Wetzel SG, Kappos L, Hoshi MM, Witte U, Radue EW, et al.  Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms. Eur Radiol. 2002;12:789–92. doi: 10.1007/s003300101086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s003300101086</ArticleId>
            <ArticleId IdType="pubmed">11960227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terré-Boliart R, Orient-López F, Guevara-Espinosa D, Ramón-Rona S, Bernabeu-Guitart M. Clavé-Civit P [Oropharyngeal dysphagia in patients with multiple sclerosis] Rev Neurol. 2004;39:707–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15514895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31:752–9. doi: 10.1097/WCO.0000000000000622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000622</ArticleId>
            <ArticleId IdType="pubmed">30300239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636. doi: 10.1212/NXI.0000000000000636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000636</ArticleId>
            <ArticleId IdType="pmc">PMC6935832</ArticleId>
            <ArticleId IdType="pubmed">31757815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al.  Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307–16. doi: 10.1016/S1474-4422(20)30067-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30067-3</ArticleId>
            <ArticleId IdType="pubmed">32199096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Restivo DA, Marchese-Ragona R, Patti F. Management of swallowing disorders in multiple sclerosis. Neurol Sci. 2006;27:s338–40. doi: 10.1007/s10072-006-0655-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-006-0655-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7. doi: 10.1084/jem.20050304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050304</ArticleId>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13:211–7. doi: 10.1038/nm1488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1488</ArticleId>
            <ArticleId IdType="pmc">PMC3429369</ArticleId>
            <ArticleId IdType="pubmed">17237795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan KH. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68:1432. doi: 10.1001/archneurol.2011.249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.249</ArticleId>
            <ArticleId IdType="pubmed">22084126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koda A, Kaneko S, Asayama S, Fujita K, Kusaka H. Successful treatment of neuromyelitis optica spectrum disorder by early initiation of plasma exchange. Rinsho Shinkeigaku. 2015;55:41–4. doi: 10.5692/clinicalneurol.55.41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5692/clinicalneurol.55.41</ArticleId>
            <ArticleId IdType="pubmed">25672865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cousins O, Girelli E, Harikrishnan S. Neuromyelitis optica: an elusive cause of dysphagia. BMJ Case Rep. 2019;12:bcr-2018–227041. doi: 10.1136/bcr-2018-227041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2018-227041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al.  Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79:1075–8. doi: 10.1136/jnnp.2008.145391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2008.145391</ArticleId>
            <ArticleId IdType="pubmed">18420727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89. doi: 10.1212/WNL.0000000000001729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729</ArticleId>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, Peschl P, et al.  Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathol. 2019;137:467–85. doi: 10.1007/s00401-018-1950-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-018-1950-8</ArticleId>
            <ArticleId IdType="pmc">PMC6514074</ArticleId>
            <ArticleId IdType="pubmed">30564980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratelade J, Bennett JL, Verkman AS. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS ONE. 2011;6:e27412. doi: 10.1371/journal.pone.0027412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0027412</ArticleId>
            <ArticleId IdType="pmc">PMC3208637</ArticleId>
            <ArticleId IdType="pubmed">22076159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, et al.  Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014;261:954–62. doi: 10.1007/s00415-014-7298-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-014-7298-7</ArticleId>
            <ArticleId IdType="pubmed">24609971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawlitzki M, Ahring S, Rolfes L, Dziewas R, Warnecke T, Suntrup‐Krueger S, et al. Dysphagia in NMOSD and MOGAD as a surrogate of brain involvement? Eur J Neurol. 2020;ene.14691. 10.1111/ene.14691.</Citation>
        </Reference>
        <Reference>
          <Citation>Sonies BC, Dalakas MC. Dysphagia in patients with the post-polio syndrome. N Engl J Med. 1991;324:1162–7. doi: 10.1056/NEJM199104253241703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199104253241703</ArticleId>
            <ArticleId IdType="pubmed">2011159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh S-Y, Kim S-H, Hyun J-W, Joung A-R, Park MS, Kim B-J, et al.  Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372. doi: 10.1001/jamaneurol.2014.2057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.2057</ArticleId>
            <ArticleId IdType="pubmed">25199960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S-H, Jeong IH, Hyun J-W, Joung A, Jo H-J, Hwang S-H, et al.  Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72:989. doi: 10.1001/jamaneurol.2015.1276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.1276</ArticleId>
            <ArticleId IdType="pubmed">26167726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352–63. doi: 10.1016/S0140-6736(19)31817-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)31817-3</ArticleId>
            <ArticleId IdType="pubmed">31495497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al.  Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–25. doi: 10.1056/NEJMoa1900866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1900866</ArticleId>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e131. doi: 10.1212/NXI.0000000000000131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000131</ArticleId>
            <ArticleId IdType="pmc">PMC4496630</ArticleId>
            <ArticleId IdType="pubmed">26185777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al.  Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251. doi: 10.1016/j.msard.2020.102251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2020.102251</ArticleId>
            <ArticleId IdType="pmc">PMC7895306</ArticleId>
            <ArticleId IdType="pubmed">32629363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280. doi: 10.1186/s12974-016-0718-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0718-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord. 2021;14:17562864211003486. doi: 10.1177/17562864211003486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/17562864211003486</ArticleId>
            <ArticleId IdType="pmc">PMC8013924</ArticleId>
            <ArticleId IdType="pubmed">33854562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rakocevic G, Alexopoulos H, Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurol. 2019;19:1. doi: 10.1186/s12883-018-1232-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-018-1232-z</ArticleId>
            <ArticleId IdType="pmc">PMC6317182</ArticleId>
            <ArticleId IdType="pubmed">30606131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006;67:1068–70. doi: 10.1212/01.wnl.0000237558.83349.d0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000237558.83349.d0</ArticleId>
            <ArticleId IdType="pubmed">17000981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al.  Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178–92. doi: 10.1093/brain/awu142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awu142</ArticleId>
            <ArticleId IdType="pmc">PMC4107739</ArticleId>
            <ArticleId IdType="pubmed">24951641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology. 2013;81:1962–4. doi: 10.1212/01.wnl.0000436617.40779.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000436617.40779.65</ArticleId>
            <ArticleId IdType="pubmed">24174585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–6. doi: 10.1056/NEJMoa01167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa01167</ArticleId>
            <ArticleId IdType="pubmed">11756577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017;82:271–7. doi: 10.1002/ana.25002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25002</ArticleId>
            <ArticleId IdType="pmc">PMC5755707</ArticleId>
            <ArticleId IdType="pubmed">28749549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RamachandranNair R, Manoj P, Rafeequ M, Girija AS. Childhood acute disseminated encephalomyelitis presenting as Foix-Chavany-Marie syndrome. J Child Neurol. 2005;20:163–5. doi: 10.1177/08830738050200021401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/08830738050200021401</ArticleId>
            <ArticleId IdType="pubmed">15794189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittard A, Abramo TJ, Arnold DH. A child with difficulty swallowing. Pediatr Emerg Care. 2009;25:525–528. doi: 10.1097/PEC.0b013e3181b0a443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PEC.0b013e3181b0a443</ArticleId>
            <ArticleId IdType="pubmed">19687713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Sun X, Li W, Li Y, Kang T, Yang X, et al.  Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with intracranial Epstein-Barr virus infection: a case report. Medicine. 2016;95:e5377. doi: 10.1097/MD.0000000000005377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000005377</ArticleId>
            <ArticleId IdType="pmc">PMC5120928</ArticleId>
            <ArticleId IdType="pubmed">27861371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mundiyanapurath S, Jarius S, Probst C, Stöcker W, Wildemann B, Bösel J. GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol. 2013;259:88–91. doi: 10.1016/j.jneuroim.2013.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.04.004</ArticleId>
            <ArticleId IdType="pubmed">23628208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al.  DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797–803. doi: 10.1212/WNL.0000000000000991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000991</ArticleId>
            <ArticleId IdType="pmc">PMC4240433</ArticleId>
            <ArticleId IdType="pubmed">25320100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oz Tuncer G, Teber S, Kutluk MG, Albayrak P, Deda G. Hashimoto’s encephalopathy presenting as pseudobulbar palsy. Childs Nerv Syst. 2018;34:1251–4. doi: 10.1007/s00381-018-3720-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-018-3720-2</ArticleId>
            <ArticleId IdType="pubmed">29368307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al.  Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126:2279–90. doi: 10.1093/brain/awg233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg233</ArticleId>
            <ArticleId IdType="pubmed">12847079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michev A, Musso P, Foiadelli T, Trabatti C, Lozza A, Franciotta D, et al.  Bickerstaff brainstem encephalitis and overlapping Guillain-Barré syndrome in children: report of two cases and review of the literature. Eur J Paediatr Neurol. 2019;23:43–52. doi: 10.1016/j.ejpn.2018.11.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpn.2018.11.008</ArticleId>
            <ArticleId IdType="pubmed">30502045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al.  Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43. doi: 10.1212/WNL.0000000000003887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003887</ArticleId>
            <ArticleId IdType="pmc">PMC5409845</ArticleId>
            <ArticleId IdType="pubmed">28381508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al.  IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4:e385. doi: 10.1212/NXI.0000000000000385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000385</ArticleId>
            <ArticleId IdType="pmc">PMC5515599</ArticleId>
            <ArticleId IdType="pubmed">28761904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X-L, Han J, Zhao H-T, Long Y-M, Zhang B-W, Wang H-Y. Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord. Ther Adv Neurol Disord. 2020;13:175628642090997. doi: 10.1177/1756286420909973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756286420909973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelly S, Kryzer TJ, Komorowski L, Miske R, Anderson MD, Flanagan EP, et al.  Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2019;6:e612. doi: 10.1212/NXI.0000000000000612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000612</ArticleId>
            <ArticleId IdType="pmc">PMC6745726</ArticleId>
            <ArticleId IdType="pubmed">31511329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallwitz U, Brock S, Schunck A, Wildemann B, Jarius S, Hoffmann F. From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. J Neuroimmunol. 2017;309:77–81. doi: 10.1016/j.jneuroim.2017.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2017.05.011</ArticleId>
            <ArticleId IdType="pubmed">28601293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castle J, Sakonju A, Dalmau J, Newman-Toker DE. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple’s disease. Nat Rev Neurol. 2006;2:566–72. doi: 10.1038/ncpneuro0287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0287</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="2">34226958</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-0460</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Dysphagia</Title>
          <ISOAbbreviation>Dysphagia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Autoimmune Neurogenic Dysphagia.</ArticleTitle>
        <Pagination>
          <StartPage>473</StartPage>
          <EndPage>487</EndPage>
          <MedlinePgn>473-487</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00455-021-10338-9</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune neurogenic dysphagia refers to manifestation of dysphagia due to autoimmune diseases affecting muscle, neuromuscular junction, nerves, roots, brainstem, or cortex. Dysphagia is either part of the evolving clinical symptomatology of an underlying neurological autoimmunity or occurs as a sole manifestation, acutely or insidiously. This opinion article reviews the autoimmune neurological causes of dysphagia, highlights clinical clues and laboratory testing that facilitate early diagnosis, especially when dysphagia is the presenting symptom, and outlines the most effective immunotherapeutic approaches. Dysphagia is common in inflammatory myopathies, most prominently in inclusion body myositis, and is frequent in myasthenia gravis, occurring early in bulbar-onset disease or during the course of progressive, generalized disease. Acute-onset dysphagia is often seen in Guillain-Barre syndrome variants and slowly progressive dysphagia in paraneoplastic neuropathies highlighted by the presence of specific autoantibodies. The most common causes of CNS autoimmune dysphagia are demyelinating and inflammatory lesions in the brainstem, occurring in patients with multiple sclerosis and neuromyelitis optica spectrum disorders. Less common, but often overlooked, is dysphagia in stiff-person syndrome especially in conjunction with cerebellar ataxia and high anti-GAD autoantibodies, and in gastrointestinal dysmotility syndromes associated with autoantibodies against the ganglionic acetyl-choline receptor. In the setting of many neurological autoimmunities, acute-onset or progressive dysphagia is a potentially treatable condition, requiring increased awareness for prompt diagnosis and early immunotherapy initiation.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Stathopoulos</LastName>
            <ForeName>Panos</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Neurology, National and Kapodistrian University of Athens Medical School, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dalakas</LastName>
            <ForeName>Marinos C</ForeName>
            <Initials>MC</Initials>
            <Identifier Source="ORCID">0000-0001-7070-1134</Identifier>
            <AffiliationInfo>
              <Affiliation>Neuroimmunology Unit, Department of Pathophysiology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece. marinos.dalakas@jefferson.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Thomas Jefferson University, Philadelphia, USA. marinos.dalakas@jefferson.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Dysphagia</MedlineTA>
        <NlmUniqueID>8610856</NlmUniqueID>
        <ISSNLinking>0179-051X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003680" MajorTopicYN="Y">Deglutition Disorders</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Autoimmune neuropathies</Keyword>
        <Keyword MajorTopicYN="N">Deglutition</Keyword>
        <Keyword MajorTopicYN="N">Deglutition disorders</Keyword>
        <Keyword MajorTopicYN="N">Dysphagia</Keyword>
        <Keyword MajorTopicYN="N">Immunotherapies</Keyword>
        <Keyword MajorTopicYN="N">Inflammatory myopathies</Keyword>
        <Keyword MajorTopicYN="N">Myasthenia gravis</Keyword>
        <Keyword MajorTopicYN="N">Neurological autoimmunity</Keyword>
        <Keyword MajorTopicYN="N">Neuromyelitis</Keyword>
        <Keyword MajorTopicYN="N">Stiff-person syndrome</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34226958</ArticleId>
        <ArticleId IdType="pmc">PMC8257036</ArticleId>
        <ArticleId IdType="doi">10.1007/s00455-021-10338-9</ArticleId>
        <ArticleId IdType="pii">10.1007/s00455-021-10338-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82. doi: 10.1016/S0140-6736(03)14368-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(03)14368-1</ArticleId>
            <ArticleId IdType="pubmed">14511932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med. 1991;325:1487–98. doi: 10.1056/NEJM199111213252107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199111213252107</ArticleId>
            <ArticleId IdType="pubmed">1658649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372:1734–47. doi: 10.1056/NEJMra1402225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1402225</ArticleId>
            <ArticleId IdType="pubmed">25923553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al.  A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360–74. doi: 10.1097/00005792-199111000-00002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-199111000-00002</ArticleId>
            <ArticleId IdType="pubmed">1659647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labeit B, Pawlitzki M, Ruck T, Muhle P, Claus I, Suntrup-Krueger S, et al.  The impact of dysphagia in myositis: a systematic review and meta-analysis. JCM. 2020;9:2150. doi: 10.3390/jcm9072150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm9072150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobloug C, Garen T, Bitter H, Stjärne J, Stenseth G, Grøvle L, et al.  Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis. 2015;74:1551–6. doi: 10.1136/annrheumdis-2013-205127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2013-205127</ArticleId>
            <ArticleId IdType="pubmed">24695011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ríos G. Retrospective review of the clinical manifestations and outcomes in puerto ricans with idiopathic inflammatory myopathies. JCR J Clin Rheumatol. 2005;11:153–6. doi: 10.1097/01.rhu.0000164820.46979.52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.rhu.0000164820.46979.52</ArticleId>
            <ArticleId IdType="pubmed">16357735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018;20:28. doi: 10.1007/s11926-018-0733-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11926-018-0733-5</ArticleId>
            <ArticleId IdType="pubmed">29637414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheehan NJ. Dysphagia and other manifestations of oesophageal involvement in the musculoskeletal diseases. Rheumatology. 2008;47:746–52. doi: 10.1093/rheumatology/ken029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/ken029</ArticleId>
            <ArticleId IdType="pubmed">18326539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, et al.  The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis. 2018;77:30–9. doi: 10.1136/annrheumdis-2017-211868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2017-211868</ArticleId>
            <ArticleId IdType="pmc">PMC5754739</ArticleId>
            <ArticleId IdType="pubmed">28855174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Basford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–7. doi: 10.4065/82.4.441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4065/82.4.441</ArticleId>
            <ArticleId IdType="pubmed">17418072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triplett JD, Pinto MV, Hosfield EA, Milone M, Liewluck T. Myopathies featuring early or prominent dysphagia. Muscle Nerve. 2020;62:344–50. doi: 10.1002/mus.26996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.26996</ArticleId>
            <ArticleId IdType="pubmed">32510670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000. doi: 10.1056/NEJM199312303292704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199312303292704</ArticleId>
            <ArticleId IdType="pubmed">8247075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. J Neurol Neurosurg Psychiatry. 2016;87:1037. doi: 10.1136/jnnp-2016-313418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2016-313418</ArticleId>
            <ArticleId IdType="pubmed">27151962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Are autoantibodies pathogenic in necrotizing myopathy? Nat Rev Rheumatol. 2018;14:251–2. doi: 10.1038/nrrheum.2018.54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrrheum.2018.54</ArticleId>
            <ArticleId IdType="pubmed">29651118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Case 22–2019: a 65-year-old woman with myopathy. N Engl J Med. 2019;381:1693. doi: 10.1056/NEJMc1911058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1911058</ArticleId>
            <ArticleId IdType="pubmed">31644862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134:3167–75. doi: 10.1093/brain/awr217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awr217</ArticleId>
            <ArticleId IdType="pubmed">21908393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taira K, Yamamoto T, Mori-Yoshimura M, Fujita S, Oya Y, Nishino I, et al.  Obstruction-related dysphagia in inclusion body myositis: cricopharyngeal bar on videofluoroscopy indicates risk of aspiration. J Neurol Sci. 2020;413:116764. doi: 10.1016/j.jns.2020.116764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2020.116764</ArticleId>
            <ArticleId IdType="pubmed">32172012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol. 2009;256:2009–13. doi: 10.1007/s00415-009-5229-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-009-5229-9</ArticleId>
            <ArticleId IdType="pmc">PMC2780610</ArticleId>
            <ArticleId IdType="pubmed">19603245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope. 1998;108:1001–5. doi: 10.1097/00005537-199807000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005537-199807000-00009</ArticleId>
            <ArticleId IdType="pubmed">9665246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6. doi: 10.1212/WNL.48.3.712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.48.3.712</ArticleId>
            <ArticleId IdType="pubmed">9065553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW. Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry. 1988;51:1542–5. doi: 10.1136/jnnp.51.12.1542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.51.12.1542</ArticleId>
            <ArticleId IdType="pmc">PMC1032771</ArticleId>
            <ArticleId IdType="pubmed">2851642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM. Inclusion body myositis presenting solely as dysphagia. Neurology. 1993;43:1241–1. doi: 10.1212/WNL.43.6.1241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.43.6.1241</ArticleId>
            <ArticleId IdType="pubmed">8170574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain. 1989;112:727–47. doi: 10.1093/brain/112.3.727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/112.3.727</ArticleId>
            <ArticleId IdType="pubmed">2543478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al.  Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132:1536–44. doi: 10.1093/brain/awp104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awp104</ArticleId>
            <ArticleId IdType="pmc">PMC2685923</ArticleId>
            <ArticleId IdType="pubmed">19454532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosmidis ML, Pikazis D, Vlachoyiannopoulos P, Tzioufas AG, Dalakas MC. Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis. Neurol Neuroimmunol Neuroinflamm. 2019;6:e581. doi: 10.1212/NXI.0000000000000581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000581</ArticleId>
            <ArticleId IdType="pmc">PMC6624107</ArticleId>
            <ArticleId IdType="pubmed">31355317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study. J Neurol Sci. 2013;334:123–5. doi: 10.1016/j.jns.2013.08.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2013.08.007</ArticleId>
            <ArticleId IdType="pubmed">23998706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al.  Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73:913–20. doi: 10.1136/annrheumdis-2012-202857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-202857</ArticleId>
            <ArticleId IdType="pubmed">23625983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMillan RA, Bowen AJ, Bayan SL, Kasperbauer JL, Ekbom DC. Cricopharyngeal myotomy in inclusion body myositis: comparison of endoscopic and transcervical approaches. Laryngoscope. 2021 doi: 10.1002/lary.29444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/lary.29444</ArticleId>
            <ArticleId IdType="pubmed">34236086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil. 2008;87:883–9. doi: 10.1097/PHM.0b013e31818a50e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PHM.0b013e31818a50e2</ArticleId>
            <ArticleId IdType="pubmed">18936555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata K, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep. 2013;6:CCRep.S10200. doi: 10.4137/CCRep.S10200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4137/CCRep.S10200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. IJGM. 2019;12:465–74. doi: 10.2147/IJGM.S198031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/IJGM.S198031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng R, Schmidt J. Impact and management of dysphagia in inflammatory myopathies. Curr Rheumatol Rep. 2020;22:74. doi: 10.1007/s11926-020-00950-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11926-020-00950-3</ArticleId>
            <ArticleId IdType="pubmed">32860119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology. 2000;55:296–8. doi: 10.1212/WNL.55.2.296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.55.2.296</ArticleId>
            <ArticleId IdType="pubmed">10908910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453–77. doi: 10.1002/(SICI)1097-4598(200004)23:4&lt;453::AID-MUS3&gt;3.0.CO;2-O.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(SICI)1097-4598(200004)23:4&lt;453::AID-MUS3&gt;3.0.CO;2-O</ArticleId>
            <ArticleId IdType="pubmed">10716755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–8. doi: 10.1038/85520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/85520</ArticleId>
            <ArticleId IdType="pubmed">11231638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verschuuren J, Strijbos E, Vincent A. Neuromuscular junction disorders. Handbook of Clinical Neurology [Internet]. Elsevier; 2016 [cited 2020 Sep 21]. p. 447–66. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780444634320000244</Citation>
        </Reference>
        <Reference>
          <Citation>Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60:1978–80. doi: 10.1212/01.WNL.0000065882.63904.53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.WNL.0000065882.63904.53</ArticleId>
            <ArticleId IdType="pubmed">12821744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray JP. Deglutition in myasthenia gravis. BJR. 1962;35:43–52. doi: 10.1259/0007-1285-35-409-43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1259/0007-1285-35-409-43</ArticleId>
            <ArticleId IdType="pubmed">14477472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llabres M. Dysphagia as the sole manifestation of myasthenia gravis. J Neurol Neurosurg Psychiatry. 2005;76:1297–300. doi: 10.1136/jnnp.2004.038430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2004.038430</ArticleId>
            <ArticleId IdType="pmc">PMC1739805</ArticleId>
            <ArticleId IdType="pubmed">16107373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang MH, King KL, Chien KY. Esophageal manometric studies in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 1988;95:281–5. doi: 10.1016/S0022-5223(19)35365-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0022-5223(19)35365-6</ArticleId>
            <ArticleId IdType="pubmed">3339894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci. 1987;505:472–99. doi: 10.1111/j.1749-6632.1987.tb51317.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1987.tb51317.x</ArticleId>
            <ArticleId IdType="pubmed">3318620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emilia-Romagna Study Group on Clinical and Epidemiological Problems in Neurology*. Incidence of myasthenia gravis in the Emilia-Romagna region: A prospective multicenter study. Neurology. 1998;51: 255–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Carpenter RJ, Mcdonald TJ, Howard FM. The otolaryngologic presentation of myasthenia gravis. Laryngoscope. 1979;89:922???928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">449537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arellano-Aguilar G, Núñez-Mojica ES, Gutiérrez-Velazco JL, Domínguez-Carrillo LG. Paraneoplastic Lambert-Eaton syndrome in a patient with disseminated metastatic cancer. CIRUE. 2019;86:1948. doi: 10.24875/CIRUE.M18000011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.24875/CIRUE.M18000011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15:113–24. doi: 10.1038/s41582-018-0110-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-018-0110-z</ArticleId>
            <ArticleId IdType="pubmed">30573759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Experience with IVIg in the treatment of patients with myasthenia gravis. Neurology. 1997;48:64S–9S. doi: 10.1212/WNL.48.Suppl_5.64S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.48.Suppl_5.64S</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol. 2020;16:601–17. doi: 10.1038/s41582-020-0400-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41582-020-0400-0</ArticleId>
            <ArticleId IdType="pmc">PMC7528717</ArticleId>
            <ArticleId IdType="pubmed">33005040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lünemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13:34–46. doi: 10.1007/s13311-015-0391-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13311-015-0391-5</ArticleId>
            <ArticleId IdType="pmc">PMC4720677</ArticleId>
            <ArticleId IdType="pubmed">26400261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia) N Engl J Med. 1956;255:57–65. doi: 10.1056/NEJM195607122550201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM195607122550201</ArticleId>
            <ArticleId IdType="pubmed">13334797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol. 2007;64:1519–23. doi: 10.1001/archneur.64.10.1519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.64.10.1519</ArticleId>
            <ArticleId IdType="pubmed">17923636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85:339–44. doi: 10.1136/jnnp-2013-305397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2013-305397</ArticleId>
            <ArticleId IdType="pubmed">23804237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arakawa M, Yamazaki M, Toda Y, Ozawa A, Kimura K. An oculopharyngeal subtype of Guillain-Barré syndrome sparing the trochlear and abducens nerves. Intern Med. 2020;59:1215–7. doi: 10.2169/internalmedicine.3395-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.3395-19</ArticleId>
            <ArticleId IdType="pmc">PMC7270762</ArticleId>
            <ArticleId IdType="pubmed">32023583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel K, Nussbaum E, Sico J, Merchant N. Atypical case of Miller-Fisher syndrome presenting with severe dysphagia and weight loss. BMJ Case Rep. 2020;13:e234316. doi: 10.1136/bcr-2020-234316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2020-234316</ArticleId>
            <ArticleId IdType="pmc">PMC7259814</ArticleId>
            <ArticleId IdType="pubmed">32467120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edvardsson B, Persson S. Polyneuritis cranialis presenting with anti-GQ1b IgG antibody. J Neurol Sci. 2009;281:125–6. doi: 10.1016/j.jns.2009.02.340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2009.02.340</ArticleId>
            <ArticleId IdType="pubmed">19324375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilyas AA, Cook SD, Mithen FA, Taki T, Kasama T, Handa S, et al.  Antibodies to GT1a ganglioside in patients with Guillain-Barré syndrome. J Neuroimmunol. 1998;82:160–7. doi: 10.1016/S0165-5728(97)00197-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0165-5728(97)00197-5</ArticleId>
            <ArticleId IdType="pubmed">9585812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Muñoz-Jordan JL, et al.  Clinical features of Guillain-Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol. 2018;75:1089. doi: 10.1001/jamaneurol.2018.1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2018.1058</ArticleId>
            <ArticleId IdType="pmc">PMC6143122</ArticleId>
            <ArticleId IdType="pubmed">29799940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orlikowski D, Terzi N, Blumen M, Sharshar T, Raphael JC, Annane D, et al.  Tongue weakness is associated with respiratory failure in patients with severe Guillain-Barré syndrome. Acta Neurol Scand. 2009;119:364–70. doi: 10.1111/j.1600-0404.2008.01107.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0404.2008.01107.x</ArticleId>
            <ArticleId IdType="pubmed">18976323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen MYM, Donofrio PD, Frederick MG, Ott DJ, Pikna LA. Videofluoroscopic evaluation of patients with Guillain-Barré syndrome. Dysphagia. 1996;11:11–3. doi: 10.1007/BF00385793.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00385793</ArticleId>
            <ArticleId IdType="pubmed">8556871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mengi T, Seçil Y, İncesu TK, Arici Ş, Akkiraz ZÖ, Gürgör N, et al.  Guillain-Barré syndrome and swallowing dysfunction. J Clin Neurophysiol. 2017;34:393–9. doi: 10.1097/WNP.0000000000000380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNP.0000000000000380</ArticleId>
            <ArticleId IdType="pubmed">28873071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Guillain-Barré syndrome: the first documented COVID-19–triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7:e781. doi: 10.1212/NXI.0000000000000781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000781</ArticleId>
            <ArticleId IdType="pmc">PMC7309518</ArticleId>
            <ArticleId IdType="pubmed">32518172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costello F, Dalakas MC. Cranial neuropathies and COVID-19: Neurotropism and autoimmunity. Neurology. 2020;95:195–6. doi: 10.1212/WNL.0000000000009921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000009921</ArticleId>
            <ArticleId IdType="pubmed">32487714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews [Internet]. Chichester, UK: John Wiley &amp; Sons, Ltd; 2010 [cited 2020 Sep 27]. p. CD002063.pub4. Available from: http://doi.wiley.com/10.1002/14651858.CD002063.pub4</Citation>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367–75. doi: 10.1001/jama.291.19.2367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.291.19.2367</ArticleId>
            <ArticleId IdType="pubmed">15150209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teramoto H, Morita A, Hara M, Ninomiya S, Shigihara S, Kusunoki S, et al.  Relapse with dysphagia in a case of chronic inflammatory demyelinating polyradiculoneuropathy. Intern Med. 2015;54:1791–3. doi: 10.2169/internalmedicine.54.4300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2169/internalmedicine.54.4300</ArticleId>
            <ArticleId IdType="pubmed">26179538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzucco S, Ferrari S, Mezzina C, Tomelleri G, Bertolasi L, Rizzuto N. Hyperpyrexia-triggered relapses in an unusual case of ataxic chronic inflammatory demyelinating polyradiculoneuropathy. Neurol Sci. 2006;27:176–9. doi: 10.1007/s10072-006-0664-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-006-0664-1</ArticleId>
            <ArticleId IdType="pubmed">16897630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, et al.  Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2:e149. doi: 10.1212/NXI.0000000000000149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000149</ArticleId>
            <ArticleId IdType="pmc">PMC4561230</ArticleId>
            <ArticleId IdType="pubmed">26401517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Schaik IN, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, et al.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17:35–46. doi: 10.1016/S1474-4422(17)30378-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(17)30378-2</ArticleId>
            <ArticleId IdType="pubmed">29122523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry. 2010;81:634–6. doi: 10.1136/jnnp.2009.177576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.177576</ArticleId>
            <ArticleId IdType="pubmed">20176598</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dyck PJ, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35:1173–6. doi: 10.1212/WNL.35.8.1173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.35.8.1173</ArticleId>
            <ArticleId IdType="pubmed">4022350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J. 2012;18:463–8. doi: 10.1097/PPO.0b013e31826c5ad5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PPO.0b013e31826c5ad5</ArticleId>
            <ArticleId IdType="pubmed">23006953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zekeridou A, Lennon VA. Neurologic autoimmunity in the era of checkpoint inhibitor cancer immunotherapy. Mayo Clin Proc. 2019;94:1865–78. doi: 10.1016/j.mayocp.2019.02.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mayocp.2019.02.003</ArticleId>
            <ArticleId IdType="pubmed">31358366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you “take the brakes off” the immune system. Ther Adv Neurol Disord. 2018;11:1756286418799864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6144585</ArticleId>
            <ArticleId IdType="pubmed">30245744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muppidi S, Vernino S. Paraneoplastic neuropathies. Continuum (Minneap Minn) 2014;20:1359–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25299287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Dalmau J. Paraneoplastic neuropathies. Curr Opin Neurol. 2013;26:489–95. doi: 10.1097/WCO.0b013e328364c020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0b013e328364c020</ArticleId>
            <ArticleId IdType="pubmed">23892629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999;67:7–14. doi: 10.1136/jnnp.67.1.7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.67.1.7</ArticleId>
            <ArticleId IdType="pmc">PMC1736440</ArticleId>
            <ArticleId IdType="pubmed">10369814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viala K, Béhin A, Maisonobe T, Léger J-M, Stojkovic T, Davi F, et al.  Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008;79:778–82. doi: 10.1136/jnnp.2007.125930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2007.125930</ArticleId>
            <ArticleId IdType="pubmed">17971432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni J, Weng L, Liu M, Yang H, Wang Y. Small cell lung cancer accompanied by tonsillar metastasis and anti-hu antibody-associated paraneoplastic neuropathy: a rare case report with long-term survival. Medicine. 2015;94:e2291. doi: 10.1097/MD.0000000000002291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000002291</ArticleId>
            <ArticleId IdType="pmc">PMC5058936</ArticleId>
            <ArticleId IdType="pubmed">26683964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeung JC, Pringle CE, Sekhon HS, Kilty SJ, Macdonald K. Bilateral vocal cord paralysis and cervicolumbar radiculopathy as the presenting paraneoplastic manifestations of small cell lung cancer: a case report and literature review. Case Rep Otolaryngol. 2016;2016:1–5. doi: 10.1155/2016/2868190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/2868190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580–7. doi: 10.1002/ana.10518.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10518</ArticleId>
            <ArticleId IdType="pubmed">12730991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, et al.  Neurosarcoidosis: presentations and management. Neurologist. 2010;16:2–15. doi: 10.1097/NRL.0b013e3181c92a72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NRL.0b013e3181c92a72</ArticleId>
            <ArticleId IdType="pubmed">20065791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brito-Zerón P, Bari K, Baughman RP, Ramos-Casals M. Sarcoidosis involving the gastrointestinal tract: diagnostic and therapeutic management. Am J Gastroenterol. 2019;114:1238–47. doi: 10.14309/ajg.0000000000000171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14309/ajg.0000000000000171</ArticleId>
            <ArticleId IdType="pubmed">30865014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishikubo K, Hyodo M, Kawakami M, Kobayashi T. A rare manifestation of cricopharyngeal myopathy presenting with dysphagia in sarcoidosis. Rheumatol Int. 2013;33:1089–92. doi: 10.1007/s00296-011-2242-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-011-2242-y</ArticleId>
            <ArticleId IdType="pubmed">22116526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thöne J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732. doi: 10.1177/1756286418805732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756286418805732</ArticleId>
            <ArticleId IdType="pmc">PMC6204624</ArticleId>
            <ArticleId IdType="pubmed">30386436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlakis PP, Alexopoulos H, Kosmidis ML, Mamali I, Moutsopoulos HM, Tzioufas AG, et al.  Peripheral neuropathies in Sjögren’s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun. 2012;39:27–33. doi: 10.1016/j.jaut.2012.01.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2012.01.003</ArticleId>
            <ArticleId IdType="pubmed">22318209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pavlakis PP, Alexopoulos H, Kosmidis ML, Stamboulis E, Routsias JG, Tzartos SJ, et al.  Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J Neurol Neurosurg Psychiatry. 2011;82:798–802. doi: 10.1136/jnnp.2010.222109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2010.222109</ArticleId>
            <ArticleId IdType="pubmed">21172862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Florica B, Aghdassi E, Su J, Gladman DD, Urowitz MB, Fortin PR. Peripheral neuropathy in patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2011;41:203–11. doi: 10.1016/j.semarthrit.2011.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2011.04.001</ArticleId>
            <ArticleId IdType="pubmed">21641018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edmonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J. 1979;2:173–5. doi: 10.1136/bmj.2.6183.173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.2.6183.173</ArticleId>
            <ArticleId IdType="pmc">PMC1595852</ArticleId>
            <ArticleId IdType="pubmed">466338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poglio F, Mongini T, Cocito D. Sensory ataxic neuropathy and esophageal achalasia in a patient with Sjogren’s syndrome. Muscle Nerve. 2007;35:532–5. doi: 10.1002/mus.20716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20716</ArticleId>
            <ArticleId IdType="pubmed">17221876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez JMS, McNally JS, Cortez MM, Hemp J, Pace LA, Clardy SL. Neuroimmunogastroenterology: at the interface of neuroimmunology and gastroenterology. Front Neurol. 2020;11:787. doi: 10.3389/fneur.2020.00787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00787</ArticleId>
            <ArticleId IdType="pmc">PMC7412790</ArticleId>
            <ArticleId IdType="pubmed">32849234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhamija R, Tan KM, Pittock SJ, Foxx-Orenstein A, Benarroch E, Lennon VA. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol. 2008;6:988–92. doi: 10.1016/j.cgh.2008.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cgh.2008.04.009</ArticleId>
            <ArticleId IdType="pmc">PMC2741093</ArticleId>
            <ArticleId IdType="pubmed">18599359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mukaino A, Minami H, Isomoto H, Hamamoto H, Ihara E, Maeda Y, et al.  Anti-ganglionic AChR antibodies in Japanese patients with motility disorders. J Gastroenterol. 2018;53:1227–40. doi: 10.1007/s00535-018-1477-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00535-018-1477-8</ArticleId>
            <ArticleId IdType="pubmed">29766276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Amico E, Zanghì A, Serra A, Murabito P, Zappia M, Patti F, et al.  Management of dysphagia in multiple sclerosis: current best practice. Expert Rev Gastroenterol Hepatol. 2019;13:47–54. doi: 10.1080/17474124.2019.1544890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17474124.2019.1544890</ArticleId>
            <ArticleId IdType="pubmed">30791843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tassorelli C, Bergamaschi R, Buscone S, Bartolo M, Furnari A, Crivelli P, et al.  Dysphagia in multiple sclerosis: from pathogenesis to diagnosis. Neurol Sci. 2008;29:360–3. doi: 10.1007/s10072-008-1044-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-008-1044-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pender MP, Ferguson SM. Dysarthria and dysphagia due to the opercular syndrome in multiple sclerosis. Mult Scler. 2007;13:817–9. doi: 10.1177/1352458506073481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458506073481</ArticleId>
            <ArticleId IdType="pubmed">17613613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan X-L, Wang H, Huang H-S, Meng L. Prevalence of dysphagia in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci. 2015;36:671–81. doi: 10.1007/s10072-015-2067-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-015-2067-7</ArticleId>
            <ArticleId IdType="pubmed">25647290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci. 1981;49:253–71. doi: 10.1016/0022-510X(81)90083-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(81)90083-6</ArticleId>
            <ArticleId IdType="pubmed">7217984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46:9–17. doi: 10.1159/000266286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000266286</ArticleId>
            <ArticleId IdType="pubmed">8162135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levinthal DJ, Rahman A, Nusrat S, O’Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:1–9. doi: 10.1155/2013/319201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/319201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solaro C, Rezzani C, Trabucco E, Amato MP, Zipoli V, Portaccio E, et al.  Prevalence of patient-reported dysphagia in multiple sclerosis patients: an Italian multicenter study (using the DYMUS questionnaire) J Neurol Sci. 2013;331:94–7. doi: 10.1016/j.jns.2013.05.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2013.05.020</ArticleId>
            <ArticleId IdType="pubmed">23747002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Danesh-Sani SA, Rahimdoost A, Soltani M, Ghiyasi M, Haghdoost N, Sabzali-Zanjankhah S. Clinical assessment of orofacial manifestations in 500 patients with multiple sclerosis. J Oral Maxillofac Surg. 2013;71:290–4. doi: 10.1016/j.joms.2012.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.joms.2012.05.008</ArticleId>
            <ArticleId IdType="pubmed">22742955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abraham S, Scheinberg LC, Smith CR, LaRocca NG. Neurologic impairment and disability status in outpatients with multiple sclerosis reporting dysphagia symptomatology. Neurorehabil Neural Repair. 1997;11:7–13. doi: 10.1177/154596839701100102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/154596839701100102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Pauw A, Dejaeger E, D’hooghe B, Carton H. Dysphagia in multiple sclerosis. Clin Neurol Neurosurg. 2002;104:345–51. doi: 10.1016/S0303-8467(02)00053-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0303-8467(02)00053-7</ArticleId>
            <ArticleId IdType="pubmed">12140103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandes AMF, de Campos DA, Eckley CA, da Silva L, Ferreira RB, Tilbery CP. Oropharyngeal dysphagia in patients with multiple sclerosis: do the disease classification scales reflect dysphagia severity? Braz J Otorhinolaryngol. 2013;79:460–5. doi: 10.5935/1808-8694.20130082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5935/1808-8694.20130082</ArticleId>
            <ArticleId IdType="pubmed">23929146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfonsi E, Bergamaschi R, Cosentino G, Ponzio M, Montomoli C, Restivo DA, et al.  Electrophysiological patterns of oropharyngeal swallowing in multiple sclerosis. Clin Neurophysiol. 2013;124:1638–45. doi: 10.1016/j.clinph.2013.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2013.03.003</ArticleId>
            <ArticleId IdType="pubmed">23601703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiesner W, Wetzel SG, Kappos L, Hoshi MM, Witte U, Radue EW, et al.  Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms. Eur Radiol. 2002;12:789–92. doi: 10.1007/s003300101086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s003300101086</ArticleId>
            <ArticleId IdType="pubmed">11960227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terré-Boliart R, Orient-López F, Guevara-Espinosa D, Ramón-Rona S, Bernabeu-Guitart M. Clavé-Civit P [Oropharyngeal dysphagia in patients with multiple sclerosis] Rev Neurol. 2004;39:707–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15514895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31:752–9. doi: 10.1097/WCO.0000000000000622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000622</ArticleId>
            <ArticleId IdType="pubmed">30300239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2020;7:e636. doi: 10.1212/NXI.0000000000000636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000636</ArticleId>
            <ArticleId IdType="pmc">PMC6935832</ArticleId>
            <ArticleId IdType="pubmed">31757815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, et al.  Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307–16. doi: 10.1016/S1474-4422(20)30067-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30067-3</ArticleId>
            <ArticleId IdType="pubmed">32199096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Restivo DA, Marchese-Ragona R, Patti F. Management of swallowing disorders in multiple sclerosis. Neurol Sci. 2006;27:s338–40. doi: 10.1007/s10072-006-0655-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-006-0655-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473–7. doi: 10.1084/jem.20050304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20050304</ArticleId>
            <ArticleId IdType="pmc">PMC2212860</ArticleId>
            <ArticleId IdType="pubmed">16087714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al.  Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med. 2007;13:211–7. doi: 10.1038/nm1488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1488</ArticleId>
            <ArticleId IdType="pmc">PMC3429369</ArticleId>
            <ArticleId IdType="pubmed">17237795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan KH. Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol. 2011;68:1432. doi: 10.1001/archneurol.2011.249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneurol.2011.249</ArticleId>
            <ArticleId IdType="pubmed">22084126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koda A, Kaneko S, Asayama S, Fujita K, Kusaka H. Successful treatment of neuromyelitis optica spectrum disorder by early initiation of plasma exchange. Rinsho Shinkeigaku. 2015;55:41–4. doi: 10.5692/clinicalneurol.55.41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5692/clinicalneurol.55.41</ArticleId>
            <ArticleId IdType="pubmed">25672865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cousins O, Girelli E, Harikrishnan S. Neuromyelitis optica: an elusive cause of dysphagia. BMJ Case Rep. 2019;12:bcr-2018–227041. doi: 10.1136/bcr-2018-227041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bcr-2018-227041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al.  Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008;79:1075–8. doi: 10.1136/jnnp.2008.145391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2008.145391</ArticleId>
            <ArticleId IdType="pubmed">18420727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89. doi: 10.1212/WNL.0000000000001729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000001729</ArticleId>
            <ArticleId IdType="pmc">PMC4515040</ArticleId>
            <ArticleId IdType="pubmed">26092914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hillebrand S, Schanda K, Nigritinou M, Tsymala I, Böhm D, Peschl P, et al.  Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat. Acta Neuropathol. 2019;137:467–85. doi: 10.1007/s00401-018-1950-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-018-1950-8</ArticleId>
            <ArticleId IdType="pmc">PMC6514074</ArticleId>
            <ArticleId IdType="pubmed">30564980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratelade J, Bennett JL, Verkman AS. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS ONE. 2011;6:e27412. doi: 10.1371/journal.pone.0027412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0027412</ArticleId>
            <ArticleId IdType="pmc">PMC3208637</ArticleId>
            <ArticleId IdType="pubmed">22076159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, et al.  Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014;261:954–62. doi: 10.1007/s00415-014-7298-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-014-7298-7</ArticleId>
            <ArticleId IdType="pubmed">24609971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pawlitzki M, Ahring S, Rolfes L, Dziewas R, Warnecke T, Suntrup‐Krueger S, et al. Dysphagia in NMOSD and MOGAD as a surrogate of brain involvement? Eur J Neurol. 2020;ene.14691. 10.1111/ene.14691.</Citation>
        </Reference>
        <Reference>
          <Citation>Sonies BC, Dalakas MC. Dysphagia in patients with the post-polio syndrome. N Engl J Med. 1991;324:1162–7. doi: 10.1056/NEJM199104253241703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199104253241703</ArticleId>
            <ArticleId IdType="pubmed">2011159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh S-Y, Kim S-H, Hyun J-W, Joung A-R, Park MS, Kim B-J, et al.  Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 2014;71:1372. doi: 10.1001/jamaneurol.2014.2057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.2057</ArticleId>
            <ArticleId IdType="pubmed">25199960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim S-H, Jeong IH, Hyun J-W, Joung A, Jo H-J, Hwang S-H, et al.  Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72:989. doi: 10.1001/jamaneurol.2015.1276.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2015.1276</ArticleId>
            <ArticleId IdType="pubmed">26167726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394:1352–63. doi: 10.1016/S0140-6736(19)31817-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(19)31817-3</ArticleId>
            <ArticleId IdType="pubmed">31495497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al.  Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381:614–25. doi: 10.1056/NEJMoa1900866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1900866</ArticleId>
            <ArticleId IdType="pubmed">31050279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e131. doi: 10.1212/NXI.0000000000000131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000131</ArticleId>
            <ArticleId IdType="pmc">PMC4496630</ArticleId>
            <ArticleId IdType="pubmed">26185777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, Pardo S, Gornall M, Cicconi S, et al.  Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Mult Scler Relat Disord. 2020;44:102251. doi: 10.1016/j.msard.2020.102251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2020.102251</ArticleId>
            <ArticleId IdType="pmc">PMC7895306</ArticleId>
            <ArticleId IdType="pubmed">32629363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm. 2016;13:280. doi: 10.1186/s12974-016-0718-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-016-0718-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsiortou P, Alexopoulos H, Dalakas MC. GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Ther Adv Neurol Disord. 2021;14:17562864211003486. doi: 10.1177/17562864211003486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/17562864211003486</ArticleId>
            <ArticleId IdType="pmc">PMC8013924</ArticleId>
            <ArticleId IdType="pubmed">33854562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rakocevic G, Alexopoulos H, Dalakas MC. Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurol. 2019;19:1. doi: 10.1186/s12883-018-1232-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-018-1232-z</ArticleId>
            <ArticleId IdType="pmc">PMC6317182</ArticleId>
            <ArticleId IdType="pubmed">30606131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006;67:1068–70. doi: 10.1212/01.wnl.0000237558.83349.d0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000237558.83349.d0</ArticleId>
            <ArticleId IdType="pubmed">17000981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al.  Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178–92. doi: 10.1093/brain/awu142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awu142</ArticleId>
            <ArticleId IdType="pmc">PMC4107739</ArticleId>
            <ArticleId IdType="pubmed">24951641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology. 2013;81:1962–4. doi: 10.1212/01.wnl.0000436617.40779.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/01.wnl.0000436617.40779.65</ArticleId>
            <ArticleId IdType="pubmed">24174585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345:1870–6. doi: 10.1056/NEJMoa01167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa01167</ArticleId>
            <ArticleId IdType="pubmed">11756577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Ann Neurol. 2017;82:271–7. doi: 10.1002/ana.25002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.25002</ArticleId>
            <ArticleId IdType="pmc">PMC5755707</ArticleId>
            <ArticleId IdType="pubmed">28749549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RamachandranNair R, Manoj P, Rafeequ M, Girija AS. Childhood acute disseminated encephalomyelitis presenting as Foix-Chavany-Marie syndrome. J Child Neurol. 2005;20:163–5. doi: 10.1177/08830738050200021401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/08830738050200021401</ArticleId>
            <ArticleId IdType="pubmed">15794189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pittard A, Abramo TJ, Arnold DH. A child with difficulty swallowing. Pediatr Emerg Care. 2009;25:525–528. doi: 10.1097/PEC.0b013e3181b0a443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PEC.0b013e3181b0a443</ArticleId>
            <ArticleId IdType="pubmed">19687713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y, Sun X, Li W, Li Y, Kang T, Yang X, et al.  Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with intracranial Epstein-Barr virus infection: a case report. Medicine. 2016;95:e5377. doi: 10.1097/MD.0000000000005377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000005377</ArticleId>
            <ArticleId IdType="pmc">PMC5120928</ArticleId>
            <ArticleId IdType="pubmed">27861371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mundiyanapurath S, Jarius S, Probst C, Stöcker W, Wildemann B, Bösel J. GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol. 2013;259:88–91. doi: 10.1016/j.jneuroim.2013.04.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2013.04.004</ArticleId>
            <ArticleId IdType="pubmed">23628208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al.  DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797–803. doi: 10.1212/WNL.0000000000000991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000991</ArticleId>
            <ArticleId IdType="pmc">PMC4240433</ArticleId>
            <ArticleId IdType="pubmed">25320100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oz Tuncer G, Teber S, Kutluk MG, Albayrak P, Deda G. Hashimoto’s encephalopathy presenting as pseudobulbar palsy. Childs Nerv Syst. 2018;34:1251–4. doi: 10.1007/s00381-018-3720-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00381-018-3720-2</ArticleId>
            <ArticleId IdType="pubmed">29368307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al.  Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126:2279–90. doi: 10.1093/brain/awg233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awg233</ArticleId>
            <ArticleId IdType="pubmed">12847079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michev A, Musso P, Foiadelli T, Trabatti C, Lozza A, Franciotta D, et al.  Bickerstaff brainstem encephalitis and overlapping Guillain-Barré syndrome in children: report of two cases and review of the literature. Eur J Paediatr Neurol. 2019;23:43–52. doi: 10.1016/j.ejpn.2018.11.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejpn.2018.11.008</ArticleId>
            <ArticleId IdType="pubmed">30502045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al.  Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43. doi: 10.1212/WNL.0000000000003887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003887</ArticleId>
            <ArticleId IdType="pmc">PMC5409845</ArticleId>
            <ArticleId IdType="pubmed">28381508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al.  IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4:e385. doi: 10.1212/NXI.0000000000000385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000385</ArticleId>
            <ArticleId IdType="pmc">PMC5515599</ArticleId>
            <ArticleId IdType="pubmed">28761904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X-L, Han J, Zhao H-T, Long Y-M, Zhang B-W, Wang H-Y. Autoimmune glial fibrillary acidic protein astrocytopathy with lesions distributed predominantly in the entire spinal cord. Ther Adv Neurol Disord. 2020;13:175628642090997. doi: 10.1177/1756286420909973.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1756286420909973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shelly S, Kryzer TJ, Komorowski L, Miske R, Anderson MD, Flanagan EP, et al.  Neurochondrin neurological autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2019;6:e612. doi: 10.1212/NXI.0000000000000612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/NXI.0000000000000612</ArticleId>
            <ArticleId IdType="pmc">PMC6745726</ArticleId>
            <ArticleId IdType="pubmed">31511329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallwitz U, Brock S, Schunck A, Wildemann B, Jarius S, Hoffmann F. From dizziness to severe ataxia and dysarthria: New cases of anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia suggest a broad clinical spectrum. J Neuroimmunol. 2017;309:77–81. doi: 10.1016/j.jneuroim.2017.05.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2017.05.011</ArticleId>
            <ArticleId IdType="pubmed">28601293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castle J, Sakonju A, Dalmau J, Newman-Toker DE. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple’s disease. Nat Rev Neurol. 2006;2:566–72. doi: 10.1038/ncpneuro0287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncpneuro0287</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
